| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Chief Financial Officer | CFO
2 companies
Brian Piekos is Chief Financial Officer at KALV, with reported holdings spanning 2 companies. Brian Piekos's net worth is not public. Form 4 filings only show shares in the companies where this person is an insider; those holdings are worth an estimated $1.9M at current prices.
Brian Piekos's largest disclosed position is in IRON as CFO, worth about $1.4M. Net of sales, the IRON filings show accumulation of 7,655 shares.
Brian Piekos has 11 Form 4 filings on record from April 2021 to April 2026, across 3 companies: Chief Financial Officer at KalVista Pharmaceuticals (KALV), 2024–2026; Chief Financial Officer at Elicio Therapeutics (ELTX), 2023–2024; CFO at Disc Medicine (IRON), 2021–2022.
The 13 reported transactions were 7 option or other derivative awards, 2 option exercises, 2 open-market sales and 1 stock award, plus smaller numbers of other types.
Counted by filing, the open-market trades come to 1 purchase worth about $72K and 2 sales worth about $98K.
The only open-market purchase was 7,655 shares of IRON at an average $9.46 on May 14, 2021, about $72K. Twelve months later IRON was down 85%.
The largest open-market sale was 4,471 shares of KALV at an average $13.45 on November 24, 2025, about $60K.
Neither of the two sales since April 2023 was marked as made under a Rule 10b5-1 trading plan.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Apr 17, 2026 | KALV Kalvista Pharmaceuticals, Inc. | Chief Financial Officer | Sale+OE | 1,862 | $20.22 | $37,642.75 | -9.3% | - | - | |
| Nov 24, 2025 | KALV Kalvista Pharmaceuticals, Inc. | Chief Financial Officer | Sale+OE | 4,471 | $13.45 | $60,139.42 | -29.8% | +16.5% | - | |
| May 14, 2021 | IRON Disc Medicine, Inc. | Chief Financial Officer | Buy | 7,655 | $9.46 | $72,431.61 | New | -56.8% | -85.3% |